Recently, several novel glucose-lowering targets have had drugs developed. This has resulted in several new drugs that have been approved for the local market to treat hyperglycaemia in patients with type 2 diabetes.

This presentation will attempt to provide:

1. A concise summary of these drugs for an Intensive Care Physician.
2. A pragmatic framework for what the non-Endocrinology Doctor should do with these drugs whilst the patient is in, and being discharged from, the Intensive Care Unit.
3. An outline of current trials evaluating glycaemia in the Intensive Care Unit.